Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 144

1.

Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial.

de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, D'Amico R, Fyles A, Baron MH, Jürgenliemk-Schulz IM, Kitchener HC, Nijman HW, Wilson G, Brooks S, Gribaudo S, Provencher D, Hanzen C, Kruitwagen RF, Smit VTHBM, Singh N, Do V, Lissoni A, Nout RA, Feeney A, Verhoeven-Adema KW, Putter H, Creutzberg CL; PORTEC Study Group.

Lancet Oncol. 2019 Sep;20(9):1273-1285. doi: 10.1016/S1470-2045(19)30395-X. Epub 2019 Jul 22. Erratum in: Lancet Oncol. 2019 Sep;20(9):e468.

2.

A Transcriptionally Distinct CXCL13+CD103+CD8+ T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer.

Workel HH, Lubbers JM, Arnold R, Prins TM, van der Vlies P, de Lange K, Bosse T, van Gool IC, Eggink FA, Wouters MCA, Komdeur FL, van der Slikke EC, Creutzberg CL, Kol A, Plat A, Glaire M, Church DN, Nijman HW, de Bruyn M.

Cancer Immunol Res. 2019 May;7(5):784-796. doi: 10.1158/2326-6066.CIR-18-0517. Epub 2019 Mar 14.

PMID:
30872264
3.

Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions.

Bagnoli M, Shi TY, Gourley C, Speiser P, Reuss A, Nijman HW, Creutzberg CL, Scholl S, Negrouk A, Brady MF, Hasegawa K, Oda K, McNeish IA, Kohn EC, Oza AM, MacKay H, Millan D, Bennett K, Scott C, Mezzanzanica D.

Cells. 2019 Feb 26;8(3). pii: E200. doi: 10.3390/cells8030200.

4.

Localization of distant metastases defines prognosis and treatment efficacy in patients with FIGO stage IV ovarian cancer.

Timmermans M, Sonke GS, Van de Vijver KK, Ottevanger PB, Nijman HW, van der Aa MA, Kruitwagen RFPM.

Int J Gynecol Cancer. 2019 Jan 21. pii: ijgc-2018-000100. doi: 10.1136/ijgc-2018-000100. [Epub ahead of print]

PMID:
30665898
5.

Vaginal hysterectomy with or without bilateral salpingo-oophorectomy may be an alternative treatment for endometrial cancer patients with medical co-morbidities precluding standard surgical procedures: a systematic review.

Kruse AJ, Ter Brugge HG, de Haan HH, Van Eyndhoven HW, Nijman HW.

Int J Gynecol Cancer. 2019 Jan 18. pii: ijgc-2018-000015. doi: 10.1136/ijgc-2018-000015. [Epub ahead of print]

PMID:
30659027
6.

Borderline tumours of the ovary: Common practice in the Netherlands.

De Decker K, Ter Brugge HG, Bart J, Kruitwagen RFPM, Nijman HW, Kruse AJ.

Gynecol Oncol Rep. 2018 Dec 10;27:25-30. doi: 10.1016/j.gore.2018.12.004. eCollection 2019 Feb.

7.

Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy.

Wortman BG, Creutzberg CL, Putter H, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LCHW, van der Steen-Banasik EM, Mens JWM, Slot A, Kroese MCS, van Triest B, Nijman HW, Stelloo E, Bosse T, de Boer SM, van Putten WLJ, Smit VTHBM, Nout RA; PORTEC Study Group.

Br J Cancer. 2018 Oct;119(9):1067-1074. doi: 10.1038/s41416-018-0310-8. Epub 2018 Oct 25.

PMID:
30356126
8.

Potent therapeutic efficacy of an alphavirus replicon DNA vaccine expressing human papilloma virus E6 and E7 antigens.

van de Wall S, Ljungberg K, Ip PP, Boerma A, Knudsen ML, Nijman HW, Liljeström P, Daemen T.

Oncoimmunology. 2018 Jul 26;7(10):e1487913. doi: 10.1080/2162402X.2018.1487913. eCollection 2018.

9.

Antigen-specific active immunotherapy for ovarian cancer.

Paijens ST, Leffers N, Daemen T, Helfrich W, Boezen HM, Cohlen BJ, Melief CJ, de Bruyn M, Nijman HW.

Cochrane Database Syst Rev. 2018 Sep 10;9:CD007287. doi: 10.1002/14651858.CD007287.pub4. Review.

10.

L1CAM expression in uterine carcinosarcoma is limited to the epithelial component and may be involved in epithelial-mesenchymal transition.

Versluis M, Plat A, de Bruyn M, Matias-Guiu X, Trovic J, Krakstad C, Nijman HW, Bosse T, de Bock GH, Hollema H.

Virchows Arch. 2018 Nov;473(5):591-598. doi: 10.1007/s00428-018-2444-8. Epub 2018 Aug 23.

PMID:
30140948
11.

Changes in (risk) behavior and HPV knowledge among Dutch girls eligible for HPV vaccination: an observational cohort study.

Donken R, Tami A, Knol MJ, Lubbers K, van der Sande MAB, Nijman HW, Daemen T, Weijmar Schultz WCM, de Melker HE.

BMC Public Health. 2018 Jul 5;18(1):837. doi: 10.1186/s12889-018-5745-6.

12.

Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative.

Auguste A, Genestie C, De Bruyn M, Adam J, Le Formal A, Drusch F, Pautier P, Crosbie EJ, MacKay H, Kitchener HC, Powell M, Pollock PM, Mileshkin L, Edmondson RJ, Nout R, Nijman HW, Creutzberg CL, Bosse T, Leary A.

Mod Pathol. 2018 Dec;31(12):1851-1861. doi: 10.1038/s41379-018-0055-1. Epub 2018 Jun 28.

PMID:
29955143
13.

Lymphadenectomy and Adjuvant Therapy Improve Survival with Uterine Carcinosarcoma: A Large Retrospective Cohort Study.

Versluis MAC, Pielsticker C, van der Aa MA, de Bruyn M, Hollema H, Nijman HW.

Oncology. 2018;95(2):100-108. doi: 10.1159/000488531. Epub 2018 May 23.

14.

Surgical Treatment of Early-Stage Cervical Cancer: A Multi-Institution Experience in 2124 Cases in The Netherlands Over a 30-Year Period.

Derks M, van der Velden J, de Kroon CD, Nijman HW, van Lonkhuijzen LRCW, van der Zee AGJ, Zwinderman AH, Kenter GG.

Int J Gynecol Cancer. 2018 May;28(4):757-763. doi: 10.1097/IGC.0000000000001228.

PMID:
29595758
15.

Implementation of laparoscopic hysterectomy for endometrial cancer over the past decade.

Wollinga T, Ezendam NPM, Eggink FA, Smink M, van Hamont D, Pijlman B, Boss E, Robbe EJ, Ngo H, Boll D, Mom CH, van der Aa MA, Kruitwagen RFLP, Nijman HW, Pijnenborg JMA.

Gynecol Surg. 2018;15(1):7. doi: 10.1186/s10397-018-1040-x. Epub 2018 Feb 27.

16.

Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial.

de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, Colombo A, Fyles A, Baron MH, Jürgenliemk-Schulz IM, Kitchener HC, Nijman HW, Wilson G, Brooks S, Carinelli S, Provencher D, Hanzen C, Lutgens LCHW, Smit VTHBM, Singh N, Do V, D'Amico R, Nout RA, Feeney A, Verhoeven-Adema KW, Putter H, Creutzberg CL; PORTEC study group.

Lancet Oncol. 2018 Mar;19(3):295-309. doi: 10.1016/S1470-2045(18)30079-2. Epub 2018 Feb 12. Erratum in: Lancet Oncol. 2018 Apr;19(4):e184.

17.

Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials.

MacKay HJ, Levine DA, Bae-Jump VL, Bell DW, McAlpine JN, Santin A, Fleming GF, Mutch DG, Nephew KP, Wentzensen N, Goodfellow PJ, Dorigo O, Nijman HW, Broaddus R, Kohn EC.

Oncotarget. 2017 Aug 3;8(48):84579-84594. doi: 10.18632/oncotarget.19961. eCollection 2017 Oct 13. Review.

18.

Centralization of ovarian cancer in the Netherlands: Hospital of diagnosis no longer determines patients' probability of undergoing surgery.

Timmermans M, Schuurman MS, Ho VKY, Massuger LF, Nijman HW, van Gorp T, Sonke GS, Kruitwagen RFPM, van der Aa MA.

Gynecol Oncol. 2018 Jan;148(1):56-61. doi: 10.1016/j.ygyno.2017.11.009. Epub 2017 Nov 10.

PMID:
29129391
19.

The prognostic benefit of tumour-infiltrating Natural Killer cells in endometrial cancer is dependent on concurrent overexpression of Human Leucocyte Antigen-E in the tumour microenvironment.

Versluis MAC, Marchal S, Plat A, de Bock GH, van Hall T, de Bruyn M, Hollema H, Nijman HW.

Eur J Cancer. 2017 Nov;86:285-295. doi: 10.1016/j.ejca.2017.09.008. Epub 2017 Oct 20.

PMID:
29059634
20.

The impact of centralization of services on treatment delay in ovarian cancer: A study on process quality.

Eggink FA, Vermue MC, Van der Spek C, Arts HJ, Apperloo MJ, Nijman HW, Niemeijer GC.

Int J Qual Health Care. 2017 Oct 1;29(6):810-816. doi: 10.1093/intqhc/mzx107.

PMID:
29025074
21.

CD103+ tumor-infiltrating lymphocytes are tumor-reactive intraepithelial CD8+ T cells associated with prognostic benefit and therapy response in cervical cancer.

Komdeur FL, Prins TM, van de Wall S, Plat A, Wisman GBA, Hollema H, Daemen T, Church DN, de Bruyn M, Nijman HW.

Oncoimmunology. 2017 Jul 24;6(9):e1338230. doi: 10.1080/2162402X.2017.1338230. eCollection 2017.

22.

Corrigendum to "Less-favourable prognosis for low-risk endometrial cancer patients with a discordant pre- versus post-operative risk stratification" [Eur J Cancer 78 (2017) 82-90].

Eggink FA, Mom CH, Bouwman K, Boll D, Becker JH, Creutzberg CL, Niemeijer GC, van Driel WJ, Reyners AK, van der Zee AG, Bremer GL, Ezendam NP, Kruitwagen RF, Pijnenborg JM, Hollema H, Nijman HW, van der Aa MA.

Eur J Cancer. 2017 Oct;84:370. doi: 10.1016/j.ejca.2017.08.003. Epub 2017 Aug 23. No abstract available.

PMID:
28844347
23.

Multi-parametric profiling of renal cell, colorectal, and ovarian cancer identifies tumour-type-specific stroma phenotypes and a novel vascular biomarker.

Corvigno S, Frödin M, Wisman GBA, Nijman HW, Van der Zee AG, Jirström K, Nodin B, Hrynchyk I, Edler D, Ragnhammar P, Johansson M, Dahlstrand H, Mezheyeuski A, Östman A.

J Pathol Clin Res. 2017 Jul 24;3(3):214-224. doi: 10.1002/cjp2.74. eCollection 2017 Jul.

24.

Surgery for patients with newly diagnosed advanced ovarian cancer: which patient, when and extent?

Eggink FA, Koopmans CM, Nijman HW.

Curr Opin Oncol. 2017 Sep;29(5):351-358. doi: 10.1097/CCO.0000000000000387. Review.

PMID:
28614136
25.

Compliance with adjuvant treatment guidelines in endometrial cancer: room for improvement in high risk patients.

Eggink FA, Mom CH, Boll D, Ezendam NPM, Kruitwagen RFPM, Pijnenborg JMA, van der Aa MA, Nijman HW.

Gynecol Oncol. 2017 Aug;146(2):380-385. doi: 10.1016/j.ygyno.2017.05.025. Epub 2017 May 25.

PMID:
28552255
26.

Markers of the p53 pathway further refine molecular profiling in high-risk endometrial cancer: A TransPORTEC initiative.

Edmondson RJ, Crosbie EJ, Nickkho-Amiry M, Kaufmann A, Stelloo E, Nijman HW, Leary A, Auguste A, Mileshkin L, Pollock P, MacKay HJ, Powell ME, Bosse T, Creutzberg CL, Kitchener HC.

Gynecol Oncol. 2017 Aug;146(2):327-333. doi: 10.1016/j.ygyno.2017.05.014. Epub 2017 May 13.

PMID:
28511869
27.

Less-favourable prognosis for low-risk endometrial cancer patients with a discordant pre- versus post-operative risk stratification.

Eggink FA, Mom CH, Bouwman K, Boll D, Becker JH, Creutzberg CL, Niemeijer GC, van Driel WJ, Reyners AK, van der Zee AG, Bremer GL, Ezendam NP, Kruitwagen RF, Pijnenborg JM, Hollema H, Nijman HW, van der Aa MA.

Eur J Cancer. 2017 Jun;78:82-90. doi: 10.1016/j.ejca.2017.03.010. Epub 2017 Apr 14. Erratum in: Eur J Cancer. 2017 Oct;84:370.

PMID:
28415003
28.

Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study.

Domingo E, Freeman-Mills L, Rayner E, Glaire M, Briggs S, Vermeulen L, Fessler E, Medema JP, Boot A, Morreau H, van Wezel T, Liefers GJ, Lothe RA, Danielsen SA, Sveen A, Nesbakken A, Zlobec I, Lugli A, Koelzer VH, Berger MD, Castellví-Bel S, Muñoz J; Epicolon consortium, de Bruyn M, Nijman HW, Novelli M, Lawson K, Oukrif D, Frangou E, Dutton P, Tejpar S, Delorenzi M, Kerr R, Kerr D, Tomlinson I, Church DN.

Lancet Gastroenterol Hepatol. 2016 Nov;1(3):207-216. doi: 10.1016/S2468-1253(16)30014-0. Epub 2016 Jul 20.

PMID:
28404093
29.

Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition.

Eggink FA, Van Gool IC, Leary A, Pollock PM, Crosbie EJ, Mileshkin L, Jordanova ES, Adam J, Freeman-Mills L, Church DN, Creutzberg CL, De Bruyn M, Nijman HW, Bosse T.

Oncoimmunology. 2016 Dec 9;6(2):e1264565. doi: 10.1080/2162402X.2016.1264565. eCollection 2017.

30.

Noninvasive monitoring of cancer therapy induced activated T cells using [18F]FB-IL-2 PET imaging.

Hartimath SV, Draghiciu O, van de Wall S, Manuelli V, Dierckx RA, Nijman HW, Daemen T, de Vries EF.

Oncoimmunology. 2016 Nov 18;6(1):e1248014. doi: 10.1080/2162402X.2016.1248014. eCollection 2017.

31.

Preliminary stop of the TOPical Imiquimod treatment of high-grade Cervical intraepithelial neoplasia (TOPIC) trial.

Koeneman MM, Kruse AJ, Kooreman LF, Zur Hausen A, Hopman AH, Sep SJ, Van Gorp T, Slangen BF, van Beekhuizen HJ, van de Sande AJ, Gerestein CG, Nijman HW, Kruitwagen RF.

BMC Cancer. 2017 Feb 7;17(1):110. doi: 10.1186/s12885-017-3108-9.

32.

Ki-67 in endometrial cancer: scoring optimization and prognostic relevance for window studies.

Kitson S, Sivalingam VN, Bolton J, McVey R, Nickkho-Amiry M, Powell ME, Leary A, Nijman HW, Nout RA, Bosse T, Renehan AG, Kitchener HC, Edmondson RJ, Crosbie EJ.

Mod Pathol. 2017 Mar;30(3):459-468. doi: 10.1038/modpathol.2016.203. Epub 2016 Dec 2.

33.

Microsatellite instability derived JAK1 frameshift mutations are associated with tumor immune evasion in endometrioid endometrial cancer.

Stelloo E, Versluis MA, Nijman HW, de Bruyn M, Plat A, Osse EM, van Dijk RH, Nout RA, Creutzberg CL, de Bock GH, Smit VT, Bosse T, Hollema H.

Oncotarget. 2016 Jun 28;7(26):39885-39893. doi: 10.18632/oncotarget.9414.

34.

CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRαβ+ CD8αβ+ T cells that can be targeted for cancer immunotherapy.

Komdeur FL, Wouters MC, Workel HH, Tijans AM, Terwindt AL, Brunekreeft KL, Plat A, Klip HG, Eggink FA, Leffers N, Helfrich W, Samplonius DF, Bremer E, Wisman GB, Daemen T, Duiker EW, Hollema H, Nijman HW, de Bruyn M.

Oncotarget. 2016 Nov 15;7(46):75130-75144. doi: 10.18632/oncotarget.12077.

35.

Size matters: Survival benefit conferred by intratumoral T cells is dependent on surgical outcome, treatment sequence and T cell differentiation.

Wouters MC, Komdeur FL, de Bruyn M, Nijman HW.

Oncoimmunology. 2016 Jan 4;5(5):e1122863. doi: 10.1080/2162402X.2015.1122863. eCollection 2016 May.

36.

Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial.

de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, Colombo A, Fyles A, Baron MH, Kitchener HC, Nijman HW, Kruitwagen RF, Nout RA, Verhoeven-Adema KW, Smit VT, Putter H, Creutzberg CL; PORTEC study group.

Lancet Oncol. 2016 Aug;17(8):1114-1126. doi: 10.1016/S1470-2045(16)30120-6. Epub 2016 Jul 7.

37.

Improved outcomes due to changes in organization of care for patients with ovarian cancer in the Netherlands.

Eggink FA, Mom CH, Kruitwagen RF, Reyners AK, Van Driel WJ, Massuger LF, Niemeijer GC, Van der Zee AG, Van der Aa MA, Nijman HW.

Gynecol Oncol. 2016 Jun;141(3):524-530. doi: 10.1016/j.ygyno.2016.04.012. Epub 2016 Apr 23.

PMID:
27090157
38.

CD103 defines intraepithelial CD8+ PD1+ tumour-infiltrating lymphocytes of prognostic significance in endometrial adenocarcinoma.

Workel HH, Komdeur FL, Wouters MC, Plat A, Klip HG, Eggink FA, Wisman GB, Arts HJ, Oonk MH, Mourits MJ, Yigit R, Versluis M, Duiker EW, Hollema H, de Bruyn M, Nijman HW.

Eur J Cancer. 2016 Jun;60:1-11. doi: 10.1016/j.ejca.2016.02.026. Epub 2016 Mar 31.

PMID:
27038842
39.

Prognostic value and clinicopathologic characteristics of L1 cell adhesion molecule (L1CAM) in a large series of vulvar squamous cell carcinomas.

Trietsch MD, Oonk MH, Hawinkels LJ, Bor R, van Eendenburg JD, Ivanova Z, Peters AA, Nijman HW, Gaarenstroom KN, Bosse T.

Oncotarget. 2016 May 3;7(18):26192-205. doi: 10.18632/oncotarget.8353.

40.

Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts.

Stelloo E, Nout RA, Osse EM, Jürgenliemk-Schulz IJ, Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, Nijman HW, Putter H, Bosse T, Creutzberg CL, Smit VT.

Clin Cancer Res. 2016 Aug 15;22(16):4215-24. doi: 10.1158/1078-0432.CCR-15-2878. Epub 2016 Mar 22.

41.

Markers of fibroblast-rich tumor stroma and perivascular cells in serous ovarian cancer: Inter- and intra-patient heterogeneity and impact on survival.

Corvigno S, Wisman GB, Mezheyeuski A, van der Zee AG, Nijman HW, Åvall-Lundqvist E, Östman A, Dahlstrand H.

Oncotarget. 2016 Apr 5;7(14):18573-84. doi: 10.18632/oncotarget.7613.

42.

TOPical Imiquimod treatment of high-grade Cervical intraepithelial neoplasia (TOPIC trial): study protocol for a randomized controlled trial.

Koeneman MM, Kruse AJ, Kooreman LFS, Zur Hausen A, Hopman AHN, Sep SJS, Van Gorp T, Slangen BFM, van Beekhuizen HJ, van de Sande M, Gerestein CG, Nijman HW, Kruitwagen RFPM.

BMC Cancer. 2016 Feb 20;16:132. doi: 10.1186/s12885-016-2187-3.

43.

Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response.

van Poelgeest MI, Welters MJ, Vermeij R, Stynenbosch LF, Loof NM, Berends-van der Meer DM, Löwik MJ, Hamming IL, van Esch EM, Hellebrekers BW, van Beurden M, Schreuder HW, Kagie MJ, Trimbos JB, Fathers LM, Daemen T, Hollema H, Valentijn AR, Oostendorp J, Oude Elberink JH, Fleuren GJ, Bosse T, Kenter GG, Stijnen T, Nijman HW, Melief CJ, van der Burg SH.

Clin Cancer Res. 2016 May 15;22(10):2342-50. doi: 10.1158/1078-0432.CCR-15-2594. Epub 2016 Jan 26.

44.

Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer.

Van Gool IC, Stelloo E, Nout RA, Nijman HW, Edmondson RJ, Church DN, MacKay HJ, Leary A, Powell ME, Mileshkin L, Creutzberg CL, Smit VT, Bosse T.

Mod Pathol. 2016 Feb;29(2):174-81. doi: 10.1038/modpathol.2015.147. Epub 2016 Jan 8.

45.

Long-Term Impact of Endometrial Cancer Diagnosis and Treatment on Health-Related Quality of Life and Cancer Survivorship: Results From the Randomized PORTEC-2 Trial.

de Boer SM, Nout RA, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, Mens JW, Slot A, Stenfert Kroese MC, Oerlemans S, Putter H, Verhoeven-Adema KW, Nijman HW, Creutzberg CL.

Int J Radiat Oncol Biol Phys. 2015 Nov 15;93(4):797-809. doi: 10.1016/j.ijrobp.2015.08.023. Epub 2015 Aug 18.

46.

A rationally designed combined treatment with an alphavirus-based cancer vaccine, sunitinib and low-dose tumor irradiation completely blocks tumor development.

Draghiciu O, Boerma A, Hoogeboom BN, Nijman HW, Daemen T.

Oncoimmunology. 2015 May 27;4(10):e1029699. eCollection 2015 Oct.

47.

Treatment Regimen, Surgical Outcome, and T-cell Differentiation Influence Prognostic Benefit of Tumor-Infiltrating Lymphocytes in High-Grade Serous Ovarian Cancer.

Wouters MC, Komdeur FL, Workel HH, Klip HG, Plat A, Kooi NM, Wisman GB, Mourits MJ, Arts HJ, Oonk MH, Yigit R, de Jong S, Melief CJ, Hollema H, Duiker EW, Daemen T, de Bruyn M, Nijman HW.

Clin Cancer Res. 2016 Feb 1;22(3):714-24. doi: 10.1158/1078-0432.CCR-15-1617. Epub 2015 Sep 18.

48.

Tattoo Delivery of a Semliki Forest Virus-Based Vaccine Encoding Human Papillomavirus E6 and E7.

van de Wall S, Walczak M, van Rooij N, Hoogeboom BN, Meijerhof T, Nijman HW, Daemen T.

Vaccines (Basel). 2015 Mar 24;3(2):221-38. doi: 10.3390/vaccines3020221.

49.

Epitope Prediction Assays Combined with Validation Assays Strongly Narrows down Putative Cytotoxic T Lymphocyte Epitopes.

Ip PP, Nijman HW, Daemen T.

Vaccines (Basel). 2015 Mar 24;3(2):203-20. doi: 10.3390/vaccines3020203.

50.

A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer.

Dijkgraaf EM, Santegoets SJ, Reyners AK, Goedemans R, Nijman HW, van Poelgeest MI, van Erkel AR, Smit VT, Daemen TA, van der Hoeven JJ, Melief CJ, Welters MJ, Kroep JR, van der Burg SH.

Oncotarget. 2015 Oct 13;6(31):32228-43. doi: 10.18632/oncotarget.4772.

Supplemental Content

Loading ...
Support Center